Study identifier:4522US/0002
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A 6-week, Randomized, Open-Label, Comparative Study to Evaluate the Efficacy and Safety of Rosuvastatin versus Atorvastatin in the treatment of Hypercholesterolaemia in African American Subjects. (ARIES)
Hypercholesterolemia
Phase 3
No
Rosuvastatin, Atorvastatin
All
1700
Interventional
18 Years +
Allocation: Randomized 
Endpoint Classification: Safety/Efficacy Study 
Intervention Model: Parallel Assignment 
Masking: Open Label 
Primary Purpose: Treatment 
Verified 01 Dec 2013 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
No locations available
| Arms | Assigned Interventions | 
|---|---|
| Experimental: 1 Rosuvastatin | - | 
| Active Comparator: 2 Atorvastatin | - |